4-ethyl-2-methyl-benzothiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 4-ethyl-2-methyl-benzothiazole
• 英文别名: 4-Aethyl-2-methyl-benzothiazol；4-Ethyl-2-methylbenzothiazole；4-ethyl-2-methyl-1,3-benzothiazole
• 化学式: C₁₀H₁₁NS
• mdl: MFCD11217448
• 分子量: 177.27
• InChiKey: AHCZZSVPHKIWOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-乙基乙酰苯胺 在 sodium sulfide 、 tetraphosphorus decasulfide 、 xylene 、 potassium hexacyanoferrate(III) 作用下， 生成 4-ethyl-2-methyl-benzothiazole
  参考文献：
  名称：

  Metzger; Plank, Bulletin de la Societe Chimique de France, 1956, p. 684,688

  摘要：

  DOI：

文献信息

• Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070072898A1

  公开（公告）日：2007-03-29

  A pyrazolo[1,5-a]pyridine derivative represented by formula (I) and salt thereof exhibit excellent MAPKAP-K2 inhibitory activity. Accordingly, medicines comprising this compound as an active ingredient are expected to be valuable for treating or preventing diseases mediated by MAPKAP-K2 such as inflammatory injury, autoimmune diseases, asteropathia destruens, cancer and/or growth of tumor.

  由式(I)表示的吡唑并[1,5-a]吡啶衍生物及其盐表现出优异的MAPKAP-K2抑制活性。因此，包含该化合物作为活性成分的药物预计对治疗或预防由MAPKAP-K2介导的疾病，如炎症损伤、自身免疫疾病、asteropathia destruens、癌症和/或肿瘤生长具有重要价值。
• AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS
  申请人：Herpin Timothy F.

  公开号：US20080275090A1

  公开（公告）日：2008-11-06

  The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y 1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y 1 receptor activity.

  本发明提供了新型的氨基苯并咪唑及其类似物，它们是选择性抑制人类P2Y1受体的抑制剂。本发明还提供了各种药物组合物和方法，用于治疗对P2Y1受体活性调节敏感的疾病。
• PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS
  申请人：Helal Christopher John

  公开号：US20140080806A1

  公开（公告）日：2014-03-20

  The present invention provides, inter alia, compounds of Formula (I) and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal. The present invention further provides compounds of Formula (Id) and pharmaceutically acceptable salts thereof as CYP3A4 selective inhibitors.

  本发明提供了公式(I)的化合物及其药学上可接受的盐，以及制备这些化合物所使用的中间体、含有这些化合物的组合物和将这些化合物用作哺乳动物中治疗中枢神经系统疾病、认知障碍、精神分裂症、痴呆和其他疾病的方法。本发明还提供了公式(Id)的化合物及其药学上可接受的盐作为CYP3A4选择性抑制剂。
• Amino-benzazoles as P2Y1 receptor inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：EP1706398B1

  公开（公告）日：2014-05-21
• US7470712B2
  申请人：——

  公开号：US7470712B2

  公开（公告）日：2008-12-30